Olvidé mi contraseña
Asóciese a SIIC en Internet para utilizar sin límites tanto siicsalud como la totalidad de los servicios bibliográficos de la institución.
Lectura recomendada:
Legacy Benefits of Blood Pressure Treatment on Cardiovascular Events are Primarily Mediated by Improved Blood Pressure Variability: The ASCOT Trial
European Heart Journal, :1-11
Lectura recomendada:
Worldwide Trends in Hypertension Prevalence and Progress in Treatment and Control from 1990 to 2019: a Pooled Analysis of 1201 Population-representative Studies with 104 Million Participants
The Lancet , 398(10304):957-980
Lectura recomendada:
Pharmacokinetics and Safety of Imeglimin in Japanese Patients with Impaired Renal Function
Journal of Clinical Pharmacology, 63(7):807-816
Lectura recomendada:
Hypercalcemia Following Discontinuation of Denosumab Therapy: A Systematic Review
Bone Reports , 15(101148):1-6
¿CUALES SON LOS EFECTOS DEL TRATAMIENTO CON FINERENONA EN PACIENTES CON ENFERMEDAD RENAL Y DIABETES TIPO 2?
Introducción:
En pacientes con diabetes tipo 2, la enfermedad renal crónica exacerba el riesgo de eventos cardiovasculares. El riesgo de eventos cardiovasculares y la incidencia de insuficiencia cardíaca aumentan cuando el cociente urinario de albúmina y creatinina es superior a 10, y cuando el índice de filtrado glomerular disminuye por debajo de 75 ml/min/1.73 m2.
Lectura recomendada:
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
New England Journal of Medicine, 385:2252-2263
Lectura recomendada:
Characteristics Predicting the Efficacy of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists on Major Adverse Cardiovascular Events in Type 2 Diabetes Mellitus: A Meta-analysis Study
Cardiovascular Diabetology, 22(153):1-13
Lectura recomendada:
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in
High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter,
Diabetes & Metabolism Journal , 47(6):818-825
Lectura recomendada:
Terlipressin in Combination with Albumin as a Therapy for Hepatorenal Syndrome in Patients Aged 65 Years or Older
Annals of Hepatology, 28(5):1-9